


**Product Name** : AZD 5069  
**Cat. No.** : PC-60618  
**CAS No.** : 878385-84-3  
**Molecular Formula** : C<sub>18</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub>  
**Molecular Weight** : 476.51  
**Target** : Chemokine Receptor (CCR and CXCR)  
**Solubility** : 10 mM in DMSO



## Biological Activity

AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable **CXCR2** antagonist that inhibits CXCL8 binding to CXCR2 with pIC<sub>50</sub> of 9.1.

AZD5069 weakly inhibits CXCL8 binding to CXCR1 with pIC<sub>50</sub><7, and no affinity for CCR2 and CCR5.

AZD5069 inhibits neutrophil chemotaxis with pA<sub>2</sub> of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1.

AZD5069 demonstrates potential activity in acute LPS-induced lung inflammation models.

## References

- Nicholls DJ, et al. *J Pharmacol Exp Ther.* 2015 May;353(2):340-50.  
Jurcevic S, et al. *Br J Clin Pharmacol.* 2015 Dec;80(6):1324-36.  
Kirsten AM, et al. *Pulm Pharmacol Ther.* 2015 Apr;31:36-41.  
Walters I, et la. *Bioorg Med Chem Lett.* 2008 Jan 15;18(2):798-803.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com